RhumbLine Advisers
AGRX

RhumbLine Advisers’s Agile Therapeutics AGRX Stock Holding History

RhumbLine Advisers’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33
Closed -$138K – 3147
2021
Q1 		$138K Sell
33
-2
-6% -$10.8K ﹤0.01% 2900
2020
Q4 		$200K Buy
35
+3
+9% +$17.7K ﹤0.01% 2839
2020
Q3 		$195K Sell
32
-5
-14% -$28.7K ﹤0.01% 2699
2020
Q2 		$208K Buy
+37
New +$192K ﹤0.01% 2752

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's AGRX Position: Q2 2021 in Review

RhumbLine Advisers sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 33 shares — an estimated $138K sold.

RhumbLine Advisers first reported a position in AGRX in Q2 2020 and held it in 4 quarters. The position peaked at $208K in Q2 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • RhumbLine Advisers reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 33 Agile Therapeutics shares in Q2 2021, an estimated $138K.
  • RhumbLine Advisers first reported a position in Agile Therapeutics in Q2 2020 and held it in 4 quarters.
  • RhumbLine Advisers's Agile Therapeutics position peaked at $208K in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.